- The
company recently completed clinical trials for its acute pain formulation,
CTL-X, which is the most advanced product in the Veritas pipeline
- Veritas
Pharma works in two directions to put together effective cannabis-based
treatments for various medical conditions
- With
the help of R&D partner Cannevert Therapeutics, Veritas is developing
solutions for various additional issues like chronic pain and sleep
disorders
Pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) is
on a mission to develop the most effective proprietary cannabis strains and
products for the treatment of various medical conditions. The company focuses
on providing both physicians and patients with conclusive evidence for the
recommendation of medical marijuana.
In the spring of 2019, Veritas announced the results of its
product clinical trials in support of the company’s commitment to developing
the most effective products (http://ibn.fm/dgy4C).
The cannabis treatment clinical trial (randomized, double-blinded, cross-over)
tested the effectiveness of the company’s vaporized CTL-X acute pain product.
Studies were carried out following GMP standards over the course of three
months. The results provide real scientific evidence of the use of cannabis for
medical purposes and, more specifically, for the treatment of acute pain.
“We believe that for millions of people suffering from acute
pain vaporized cannabis can potentially reduce the need for other medications,
including opioids. From results of this study, clinicians will have a better
understanding for specific dosage and delivery of cannabis for acute pain,”
Veritas Medical Director Dr. Scott Alexander stated in a news release.
Veritas’ innovative research and development approach aims
to solve the critical need for scientific research to support claims about the
effectiveness of cannabis-based treatments. Through its research and
development subsidiary, Cannevert Therapeutics Ltd., Veritas is developing
innovative products for the treatment of various medical conditions like
chronic and acute pain, sleep disorders and palliative care.
Cannevert has screened numerous cannabis strains to pinpoint
their potential in treating chronic pain and reducing the need for opioid
administration. Acute pain treatment CTL-X is the most advanced product in the
Veritas pipeline and therefore the focus of its clinical trial efforts.
Veritas is also concerned with sleep disorders and the
growing prominence of the conditions. Studies show that Americans are now
getting one to two hours less sleep than previous generations (http://ibn.fm/yIp3V). In 1942,
only 11 percent of Americans slept six hours or less per night. By 2013, the
number had increased to 40 percent of the adult population, the American
Association of Retired Persons (AARP) reported.
Through its research, Veritas is attempting to identify
cannabis as a reliable solution to this growing problem. There is some
anecdotal evidence, and Cannevert is working to develop biological assays to
identify the most effective strain for the treatment of insomnia, parasomnia,
chronic fatigue syndrome and others.
Based at the University of British Columbia, Cannevert has
brought together a team of pharmacologists, chemists and anesthetists who have
substantial prior experience in drug development. Through the partnership,
Veritas gains the technical ability to achieve its effective treatment
development vision.
For more information, visit the company’s website at www.VeritasPharmaInc.com
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment